Study to Evaluate Safety and Activity of TRL345 in Healthy Volunteers
A Phase 1, Double-Blind, Single Ascending Dose Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of TRL345 in Healthy Volunteers
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
This PHASE1 trial investigates Healthy Volunteers and is currently completed. National Institute of Allergy and Infectious Diseases (NIAID) leads this study, which shows 8 recorded versions since 2023 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
8 versions recorded-
May 2025 — Present [monthly]
Completed PHASE1
Status: Active Not Recruiting → Completed
-
Dec 2024 — May 2025 [monthly]
Active Not Recruiting PHASE1
Status: Recruiting → Active Not Recruiting
-
Sep 2024 — Dec 2024 [monthly]
Recruiting PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE1
-
Oct 2023 — Jul 2024 [monthly]
Recruiting PHASE1
Status: Not Yet Recruiting → Recruiting
▶ Show 3 earlier versions
-
May 2023 — Oct 2023 [monthly]
Not Yet Recruiting PHASE1
-
Apr 2023 — May 2023 [monthly]
Not Yet Recruiting PHASE1
-
Jul 2022 — Apr 2023 [monthly]
Not Yet Recruiting PHASE1
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- National Institute of Allergy and Infectious Diseases (NIAID)
- Trellis Bioscience LLC
For direct contact, visit the study record on ClinicalTrials.gov .